Celator Pharmaceuticals
Princeton
About Celator Pharmaceuticals
Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $175.6M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2016)
- Ticker: nasdaq:CPXX
- Website: celatorpharma.com
- Phone: (609) 243-0123
Industries & Categories
Biopharma, Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/celator-pharmaceuticals-2230244 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.